Stephen J. Forman - 31 Mar 2025 Form 4 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Role
Director
Signature
/s/ Stephen Forman
Issuer symbol
LIXT
Transactions as of
31 Mar 2025
Net transactions value
$0
Form type
4
Filing time
02 Apr 2025, 10:36:31 UTC
Previous filing
22 Jan 2025
Next filing
08 Jul 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIXT Options to Purchase Common Stock Award $0 +5,851 $0.000000 5,851 31 Mar 2025 Common 5,851 $1.21 Direct F1
holding LIXT Options to Purchase Common Stock 3,030 31 Mar 2025 Common 3,030 $2.33 Direct
holding LIXT Options to Purchase Common Stock 3,858 31 Mar 2025 Common 3,858 $1.30 Direct
holding LIXT Options to Purchase Common Stock 10,000 31 Mar 2025 Common 10,000 $2.37 Direct
holding LIXT Options to Purchase Common Stock 3,018 31 Mar 2025 Common 3,018 $2.37 Direct
holding LIXT Options to Purchase Common Stock 10,000 31 Mar 2025 Common 10,000 $5.88 Direct
holding LIXT Options to Purchase Common Stock 10,000 31 Mar 2025 Common 10,000 $7.45 Direct
holding LIXT Options to Purchase Common Stock 10,000 31 Mar 2025 Common 10,000 $30.30 Direct
holding LIXT Options to Purchase Common Stock 5,000 31 Mar 2025 Common 5,000 $32.10 Direct
holding LIXT Warrants to Purchase Common Stock 2,105 31 Mar 2025 Common 2,105 $57.00 By Stephen Forman Living Trust
holding LIXT Options to Purchase Common Stock 833 31 Mar 2025 Common 833 $9.00 Direct
holding LIXT Options to Purchase Common Stock 833 31 Mar 2025 Common 833 $66.00 Direct
holding LIXT Warrants to Purchase Common Stock 1,667 31 Mar 2025 Common 1,667 $60.00 By Stephen Forman Living Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective March 31, 2025, the reporting person was granted stock options to purchase an aggregate of 5,851 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.